By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has completed the acquisition of Celera for around $671 million.

The Madison, NJ-based lab testing firm said that it completed the deal through a short-form merger after its tender offer expired last week. Each share of Celera common stock was converted into the right to receive the same $8 in cash, without interest and less any withholding of taxes, that was paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.